A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.
Phase 1
Active, not recruiting
- Conditions
- Moderately to severely active ulcerative colitisTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2024-514561-20-00
- Lead Sponsor
- Abivax
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method